Institut National De La Sante Et De La Recherche Medicale

UniversitÉ De Paris

Orega Biotech

Mablife

Centre National De La Recherche Scientifique

Medecine Et Innovation

Dana-farber-cancer Institute Inc.

Universitè De Montpellier

Université Paris Diderot-Paris 7

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut Jean Godinot

Institut RÉgional Du Cancer De Montipellier

Monoclonal Antibodies Therapeutics

Assistance Publique-hopitaux De Paris

Elsalys Biotech

Armand Bensussan

Laurence Boumsell

Jean-Francois Eliaou

Allessandro Moretta

Martine Bagot

Nathalie Bonnefoy

Jeremy Bastid

Gilles Alberici

Daniel Zagury

Yves Levy

Jean Kadouche

Helene Le Buanec

Philippe Le Bouteiller

Sophie Duchez

Valerie Schiavon

Nathalie Bonnefoy-Berard

Gordon James Freeman

Lee M Nadler

Vassiliki A Boussiotis

Bruno Robert

Pierre Martineau

Joachim L Schultze

Marie-Françoise Belin

Myriam Chentouf

Kathryn T Hall

Pascale Giraudon

Anne Marie-Cardine

Jérôme Giustiniani

Phillipe Le Bouteiller

Jean-Christophe Bories

Maxime Fayon

Carolina Martinez-Cingolani

Jérémy Bastid

Jean-François Eliaou

Laurence Boumselle

CD38 is also expressed in a variety of malignant hematological diseases, including multiple myeloma. In the present invention, the inventors have generated a new antibody against CD38 that could be suitable for producing bispecific antibodies as well as CAR-T cells. In particular, the inventors report the development of Bi38-3, a new bispecific T cell engager that targeted CD38 on MM cells and recruited cytotoxic T cells through the CD3ε. Bi38-3 lacked the Fc region of natural mAb, which contributes to resistance processes, but triggered T cells to proliferate, release cytokine and lyse CD38 positive MM cells in vitro. Similarly, Bi38-3 induced autologous T cells to eliminate tumor plasma cells isolated from MM patients both at diagnosis and at relapse. The cytotoxicity triggered by Bi38-3 was restricted to cells expressing high levels of CD38 and preserved the integrity of T, B and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in an MM1.S xenograft mouse model of human MM. Taken together, the results show that the antibody of the present invention is an effective reagent to specifically eliminate CD38 positive malignant cells without significantly affecting CD38 lowly expressing cells and represents a promising novel immunotherapeutic tool for the treatment of malignant hematological diseases, and especially multiple myeloma.

Antibodies having specificity for CD38 and uses thereof

The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.

Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity

The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4Foxp3regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR&#x3b1;&#x3b2;+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR&#x3b1;&#x3b2;+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof

The present invention relates to a method for ex vivo generating and expanding &#x3b3;&#x3b4; Foxp3regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR&#x3b3;&#x3b4; unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR&#x3b3;&#x3b4; unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR&#x3b3;&#x3b4;+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo &#x3b3;&#x3b4; Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR&#x3b3;&#x3b4;+ Foxp3+.

Ex vivo generation of &#x3b3;&#x3b4; Foxp3regulatory T cells and therapeutic uses thereof

The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

Monoclonal antibodies binding to the CD160 transmembrane isoform

The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.

Antagonists of IL-17 isoforms and their uses

The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.

Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

The invention relates to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.

The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.

IL-17 antagonist antibodies

The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.

Means for the diagnosis and therapy of CTCL

The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.

Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2

The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.

Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells

Growing community of inventors

Paris, France

Armand Bensussan